Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
63
TNDM Quote, Financials, Valuation and Earnings
Last price:
$20.71
Seasonality move
:
8.04%
Day range:
$19.70 - $20.77
52-week range:
$9.98 - $38.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.37x
P/B ratio:
10.56x
Volume:
1.2M
Avg. volume:
2.4M
1-year change:
-35.84%
Market cap:
$1.4B
Revenue:
$940.2M
EPS (TTM):
-$3.05
Analysts' Opinion
-
Consensus RatingTandem Diabetes Care, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.52, Tandem Diabetes Care, Inc. has an estimated upside of 8.76% from its current price of $20.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 32.4% downside risk from its current price of $20.71.
Fair Value
-
According to the consensus of 20 analysts, Tandem Diabetes Care, Inc. has 8.76% upside to fair value with a price target of $22.52 per share.
TNDM vs. S&P 500
-
Over the past 5 trading days, Tandem Diabetes Care, Inc. has underperformed the S&P 500 by -0.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tandem Diabetes Care, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tandem Diabetes Care, Inc. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Tandem Diabetes Care, Inc. reported revenues of $249.3M.
Earnings Growth
-
Tandem Diabetes Care, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Tandem Diabetes Care, Inc. reported earnings per share of -$0.31.
Enterprise value:
1.5B
EV / Invested capital:
2.64x
Price / LTM sales:
1.37x
EV / EBIT:
--
EV / Revenue:
1.52x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-61.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$536M
Return On Assets:
-22.12%
Net Income Margin (TTM):
-20.2%
Return On Equity:
-110.24%
Return On Invested Capital:
-31.16%
Operating Margin:
-8.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $771.4M | $854.4M | $1B | $244M | $249.3M | |
| Gross Profit | $389.9M | $425.4M | $536M | $124.7M | $134.3M | |
| Operating Income | -$137.2M | -$133.6M | -$98.2M | -$26.1M | -$20.1M | |
| EBITDA | -$121.8M | -$117.2M | -$80.7M | -$21.9M | -$15.6M | |
| Diluted EPS | -$3.22 | -$1.94 | -$3.05 | -$0.35 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $754.9M | $834.3M | $758.1M | $752.8M | $616.9M | |
| Total Assets | $850.3M | $1B | $939.9M | $957.7M | $874.7M | |
| Current Liabilities | $119.7M | $173.6M | $187.1M | $259.3M | $252.5M | |
| Total Liabilities | $460.6M | $625.7M | $625.9M | $720M | $741.7M | |
| Total Equity | $389.7M | $421.8M | $314M | $237.7M | $133M | |
| Total Debt | $316M | $409.9M | $400.6M | $457.9M | $427.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.8M | $6.3M | -$8.8M | $26.8M | $8.3M | |
| Cash From Investing | -$33.4M | -$45.1M | $92.9M | -$19.9M | $20.5M | |
| Cash From Financing | $7.6M | $8.7M | -$43.7M | -$4.5M | -$1.6M | |
| Free Cash Flow | -$39.7M | -$12.6M | -$25.1M | $21.5M | $4.2M | |
TNDM
Sector
Market Cap
$1.4B
$28.4M
Price % of 52-Week High
54.1%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
1.03%
-1.32%
1-Year Price Total Return
-35.84%
-22.19%
Beta (5-Year)
1.685
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$20.73
200-day SMA
Buy
Level
$17.35
Bollinger Bands (100)
Buy
Level
11.82 - 17.46
Chaikin Money Flow
Buy
Level
71.5M
20-day SMA
Buy
Level
$19.00
Relative Strength Index (RSI14)
Buy
Level
63.66
ADX Line
Buy
Level
30.47
Williams %R
Neutral
Level
-27.35
50-day SMA
Buy
Level
$16.17
MACD (12, 26)
Buy
Level
1.39
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
104.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7423)
Sell
CA Score
(Annual)
Level (-1.4627)
Buy
Beneish M-Score
(Annual)
Level (-3.344)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.4911)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, TNDM has received 6 Buy ratings 14 Hold ratings, and 0 Sell ratings. The TNDM average analyst price target in the past 3 months is $22.52.
-
Where Will Tandem Diabetes Care, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tandem Diabetes Care, Inc. share price will rise to $22.52 per share over the next 12 months.
-
What Do Analysts Say About Tandem Diabetes Care, Inc.?
Analysts are divided on their view about Tandem Diabetes Care, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tandem Diabetes Care, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Tandem Diabetes Care, Inc.'s Price Target?
The price target for Tandem Diabetes Care, Inc. over the next 1-year time period is forecast to be $22.52 according to 20 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is TNDM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tandem Diabetes Care, Inc. is a Hold. 14 of 20 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TNDM?
You can purchase shares of Tandem Diabetes Care, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tandem Diabetes Care, Inc. shares.
-
What Is The Tandem Diabetes Care, Inc. Share Price Today?
Tandem Diabetes Care, Inc. was last trading at $20.71 per share. This represents the most recent stock quote for Tandem Diabetes Care, Inc.. Yesterday, Tandem Diabetes Care, Inc. closed at $20.71 per share.
-
How To Buy Tandem Diabetes Care, Inc. Stock Online?
In order to purchase Tandem Diabetes Care, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TNDM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TNDM
Sector
P/E ratio
--
23.66x
PEG ratio
-0.12x
-0.01x
P/B ratio
10.56x
1.84x
Price / LTM sales
1.37x
1.60x
Growth Metrics
TNDM
Sector
Revenue growth
2.17%
4.85%
Earnings growth
11.84%
11.15%
Revenue (5-year growth)
21.01%
6.45%
Earnings forecast
-$0.34
-$0.20
Profitability
TNDM
Sector
Profitability FY 2024
$474.9M
$3.6M
Return on invested capital
-31.16%
-30.98%
Return on assets
-22.12%
-27.62%
Return on equity
-110.24%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
5
Balance Sheet
TNDM
Sector
Total cash
$319.1M
$27.2M
Short term investments
$369.1M
$25.7M
Total assets
$967.7M
$79.9M
Long term debt
$427.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
